Einhorn, L.H., Brames, M.J., Dreicer, R., Nichols, C.R., Cullen, M.T., Jr., & Bubalo, J. (2007). Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Supportive Care in Cancer, 15(11),1293-1300.
To evaluate the safety and efficacy of palonosetron plus dexamethasone for patients receiving multiple-day, highly emetogenic chemotherapy (HEC)
Patients received 0.25 mg IV palonosetron as an infusion 30 minutes before chemotherapy on days 1, 3, and 5 plus dexamethasone 20 mg IV on days 1 and 2, 8 mg orally twice daily on days 6 and 7, and 4 mg orally twice daily on day 8. Given the high receptor-binding affinity and prolonged half-life of palonosetron, this study involved alternate day dosing (days 1, 3, and 5 rather than days 1-3) combined with a standard dexamethasone regimen for multiple-day, cisplatin-based chemotherapy.
The study consisted of 41 patients with germ cell tumors.
This was a nonrandomized trial.
The following data was collected.